Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study

Background Studies based on molecular testing of oral/nasal swabs underestimate SARS-CoV-2 infection due to issues with test sensitivity, test timing and selection bias. The objective of this study was to report the presence of SARS-CoV-2 antibodies, consistent with previous infection. Design This multicentre observational cohort study, conducted between 16 April to 3 July 2020 at 5 UK sites, recruited children of healthcare workers, aged 2–15 years. Participants provided blood samples for SARS-CoV-2 antibody testing and data were gathered regarding unwell contacts and symptoms. Results 1007 participants were enrolled, and 992 were included in the final analysis. The median age of participants was 10·1 years. There were 68 (6.9%) participants with positive SARS-CoV-2 antibody tests indicative of previous SARS-CoV-2 infection. Of these, 34/68 (50%) reported no symptoms prior to testing. The presence of antibodies and the mean antibody titre was not influenced by age. Following multivariable analysis four independent variables were identified as significantly associated with SARS-CoV-2 seropositivity: known infected household contact OR=10.9 (95% CI 6.1 to 19.6); fatigue OR=16.8 (95% CI 5.5 to 51.9); gastrointestinal symptoms OR=6.6 (95% CI 3.0 to 13.8); and changes in sense of smell or taste OR=10.0 (95% CI 2.4 to 11.4). Discussion Children demonstrated similar antibody titres in response to SARS-CoV-2 irrespective of age. Fatigue, gastrointestinal symptoms and changes in sense of smell or taste were the symptoms most strongly associated with SARS-CoV-2 antibody positivity. Trial registration number NCT0434740.

[1]  M. Dake,et al.  Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure , 2020, medRxiv.

[2]  M. Hernán,et al.  Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.

[3]  Morten Nielsen,et al.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19 , 2020, Cell.

[4]  A. Giacomelli,et al.  Seroprevalence of SARS-CoV-2 IgG significantly varies with age: results from a mass population screening (SARS-2-SCREEN-CdA). , 2020, medRxiv.

[5]  S. Lee,et al.  Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients , 2020, Emerging infectious diseases.

[6]  A. Flahault,et al.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.

[7]  S. de Lusignan,et al.  COVID-19 in children: analysis of the first pandemic peak in England , 2020, Archives of Disease in Childhood.

[8]  Supinda Bunyavanich,et al.  Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. , 2020, JAMA.

[9]  A. Osterhaus,et al.  Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19) , 2020, The Journal of pathology.

[10]  A. Hale,et al.  A cautionary tale of false-negative nasopharyngeal COVID-19 testing , 2020, IDCases.

[11]  M. Lenge,et al.  Children with Covid-19 in Pediatric Emergency Departments in Italy , 2020, The New England journal of medicine.

[12]  X. Tang,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[13]  Lei Liu,et al.  Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  K. Tao,et al.  The characteristics of household transmission of COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Wei Zhou,et al.  Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor , 2020, Pharmacological Research.

[16]  Kari Stefansson,et al.  Spread of SARS-CoV-2 in the Icelandic Population , 2020, The New England journal of medicine.

[17]  T. Skoff,et al.  Coronavirus Disease 2019 in Children — United States, February 12–April 2, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[18]  A. Tagarro,et al.  Screening and Severity of Coronavirus Disease 2019 (COVID-19) in Children in Madrid, Spain. , 2020, JAMA pediatrics.

[19]  Haiyan Qiu,et al.  Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study , 2020, The Lancet Infectious Diseases.

[20]  G. Wong,et al.  SARS-CoV-2 Infection in Children , 2020, The New England journal of medicine.

[21]  Zhongyi Jiang,et al.  Epidemiology of COVID-19 Among Children in China , 2020, Pediatrics.

[22]  Peng Wu,et al.  Detection of Covid-19 in Children in Early January 2020 in Wuhan, China , 2020, The New England journal of medicine.

[23]  Zhongyi Jiang,et al.  Epidemiology of COVID-19 Among Children in China , 2020, Pediatrics.

[24]  M. Lipsitch,et al.  Defining the Epidemiology of Covid-19 - Studies Needed. , 2020, The New England journal of medicine.

[25]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[26]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[27]  Matthias Egger,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.